Sleep Apnea Devices Market Outlook:
Sleep Apnea Devices Market size was over USD 6.33 billion in 2024 and is projected to reach USD 12.11 billion by 2034, growing at around 6.7% CAGR during the forecast period i.e., between 2025-2034. In the year 2025, the industry size of sleep apnea devices is evaluated at USD 6.69 billion.
Key Sleep Apnea Devices Market Insights Summary
Asia Pacific is expected to account for the largest sleep apnea devices market share of 33.1% throughout the forecast period.
North America is projected to generate substantial revenue from this sector during the analysis period.
Sleep apnea masks are projected to capture the highest share of 50.5% in the sleep apnea devices market by the end of 2037.
The home healthcare segment is anticipated to lead among end users during the evaluated timeframe.
Key Growth Trends
- Innovations in technology for related devices
- Increasing access and expenditure in healthcare
Key Players
Philips Respironics, BMC Medical Co. Ltd., Curative Medical Inc., SOMNOmedics GmbH, Itamar Medical Ltd., Nihon Kohden Corporation, ResMed Inc., Natus Medical Incorporated, Invacare Corporation, Compumedics Limited., Signifier Medical Technologies Limited
Market Size and Growth Projections
- 2024 Market Size: USD 6.33 billion
- 2025 Market Size: USD 6.69 billion
- Projected Market Size: USD 12.11 billion by 2034
- Growth Forecasts: 6.7% CAGR (2025-2034)
- Largest Region: Asia Pacific (33.1% Share by 2034)
- Fastest Growing Region: North America
Growth in this market is primarily driven by the increased prevalence of chronic conditions and the aging population, which is expected to increase the load of obstructive sleep apnea (OSA). Comorbidities such as diabetes, hypertension, cardiovascular diseases (CVD), and obesity are commonly associated with this condition. As per an NLM article from July 2023, around 936.0 million habitats aged between 30 and 69 from around the globe were suffering from this sleeping disorder. It further mentioned that over 40.0% of the adults with serious OSA were diagnosed with obesity. Similarly, another journal from the American Heart Association released in June 2021 established that 80.0% of patients with resistant hypertension are at high risk of developing this ailment.
These figures indicate the heightening demand for effective solutions for treatment and prevention, fuelling the market. Without treatment, OSA may increase the rate of mortality from heart attack, stroke, diabetes, heart failure, and irregular heartbeat. In this regard, in 2020, a study on the effect of therapy absence on mortality and incidence was published by the ERS Publications. The cohort observed a 5.0% higher possibility of death in obstructive sleep apnoea–hypopnoea syndrome (OSAHS) residents who were not using continuous positive airway pressure (CPAP). This is pushing both patients and public health organizations to invest more in this field.
Comparative Analysis on Incidence Rate of Selective Ailments due to OSAHS (2020)
|
Disease Category |
Incidence Rate in CPAP Users (in %) |
Incidence Rate in CPAP Non-Users (in %) |
|
Type II Diabetes Mellitus |
18.7 |
27.9 |
|
Ischaemic Heart Disease |
12.7 |
25.5 |
|
Myocardial Infarction |
4.2 |
14.7 |
Source: ERS Publications
Sleep Apnea Devices Market Growth Drivers and Challenges:
Growth Drivers
-
Innovations in technology for related devices: Advancements in design, functionality, and technology are revolutionizing the pipeline efficacy of the market. New devices are now becoming more comfortable, user-friendly, and durable, which is attracting a wider consumer base. For instance, in September 2023, Signifier Medical Technologies introduced a novel pathway of treating OSA, Neuromuscular Electrical Stimulation (NMES), at the 2023 World Sleep Congress. Further, in February 2024, ResMed brought its AirCurve 11 series devices to the market, combining the benefits of inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP) digitally.
- Increasing access and expenditure in healthcare: As the understanding of the importance of applying therapies for OSA grows, engagement in the market heightens. With the increasing public and private spending on the improvement of healthcare infrastructure, access to such advanced curatives rises. According to the 2021 NLM report, the expense for each quality-adjusted life year (QALY) for this medical illness in the U.S. accounted for USD 50,000.0, aligning with the threshold of willingness to pay (WTP). Additionally, the ability to reduce the economic burden for associated residents is also influencing them to adopt such systems.
Challenges
-
Delay and lack in diagnosis: Despite the enlarging patient pool, a majority of residents worldwide remain undiagnosed, causing unwanted disease progression. As per NLM, over 58.0% of the population with sick sinus syndrome having a pacemaker implantation were unaware of their OSA symptoms in 2023. This lack of awareness may impact the effectiveness of solutions available in the market. This raises concerns about product failure, hindering brand reputation, and restricting wide adoption.
- Limitations in market availability and competency: Access to advanced healthcare is still inadequate in underserved regions, limiting distribution channels for the market. Financial constraints, coupled with insufficient resources, result in a lack of availability in these marketplaces. In addition, the resistive tendency among consumers about the blind reliance on traditional approaches and vendor lock-in often hampers the exposure for new entrants and latest developments, restricting the market’s progression.
Sleep Apnea Devices Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2034 |
|
CAGR |
6.7% |
|
Base Year Market Size (2024) |
USD 6.33 billion |
|
Forecast Year Market Size (2034) |
USD 12.11 billion |
|
Regional Scope |
|
Sleep Apnea Devices Market Segmentation:
Product Type Segment Analysis
The sleep apnea masks are anticipated to hold the largest share of 50.5% in the sleep apnea devices market by the end of 2037. The segment’s growth is primarily attributed to the worldwide use of CPAP machines in disease management. There are many cohorts of clinical evidence demonstrating the effectiveness of this subtype in reducing the risk of gastric content aspiration and CO2 rebreathing, even after the device relapse. This adds up to the product’s safety profile, solidifying consumer trust and preference. This is testified by the lucrative revenues generated from this segment. For instance, by September 2024, Resmed secured a net global revenue of USD 442.0 million from its mask portfolio. This further inspired the company to launch a new fabric nasal CPAP mask, AirTouch N30i.
End user Segment Analysis
In terms of end user, the home healthcare segment is predicted to dominate the sleep apnea devices market over the assessed timeframe. This segment is gaining traction due to the convenience and affordability of remote disease management, particularly for older residents. On this note, the Healthcare Federation of India revealed that, nationally, the industry size of this medical setting attained USD 5.4 billion in 2022 and is projected to be valued at USD 19.9 billion by 2025. This represents a wider scope of business for this segment, inspiring global pioneers to focus on this category. Following this cohort, in May 2023, Signifier Medical Technologies partnered with Sunrise to develop a home sleep testing device for habitats with OSA.
Our in-depth analysis of the global sleep apnea devices global market includes the following segments:
|
Disease Type |
|
|
Product Type |
|
|
Patient Demographics |
|
|
End user |
|
|
Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportSleep Apnea Devices Market Regional Analysis:
APAC Market Insights
Asia Pacific is projected to hold the largest sleep apnea devices market share of 33.1% throughout the analysed timeline. The region’s proprietorship is owing to a growing geriatric population and rising prevalence of high-risk conditions such as cardiovascular diseases, hypertension, and diabetes. In this regard, a research team from Xi'an Jiaotong University disclosed that approximately 649.0 million habitats in Asia were aged 60 and over in 2022. They also predicted this number to reach 1.3 billion by 2050. Simultaneously, the International Diabetes Federation (IDF) reported that the numbers of adults with diabetes are projected to rise by 68.0% and 26.0% in Southeast Asia and the Western Pacific region, respectively, by 2045. This signifies the inflating demand in the market.
China is augmenting the sleep apnea devices market with its large consumer base and strong emphasis on the medical device industry. The population of OSA residents in this country reached 176.0 million in 2022, among which 66.0 million ranged between moderate and severe (NLM). On the other hand, the International Trade Administration projected the medical device industry of China to attain USD 48.8 billion by 2026, exhibiting a CAGR of 8.3%. This scenario embarks on the presence of great business opportunities for both domestic and international leaders.
North America Market Insights
North America is expected to garner significant revenue from the sleep apnea devices market during the assessed period. This region is pledged with the ongoing developments and heightening volume of obese habitats. According to the 2024 IHME database, the projection of the obese populations among adults (above 25) and youngsters (5-24) in the U.S. are 213.0 million and 43.0 million, respectively, by 2050. This demography is attracting established leaders in this sector to participate in this landscape. For instance, in May 2023, Acurable shared its plans for the commercial launch of its FDA-approved compact wearable OSA device, AcuPebble SA100, for adults in the North America marketplace. This U.S. debut was backed by a series A funding of USD 12.0 million.
The U.S. sleep apnea devices market is propagating with the supportive regulatory framework and spreading awareness. Considering the high-risk factor of OSA in increasing CVD-related mortality, several public and private organizations are proactively taking part in educating people about the health impact and available therapeutics of this clinical ailment. For instance, in February 2023, the American Academy of Sleep Medicine commenced a nationwide campaign, More than a Snore, to provide the required knowledge about OSA to the general public. The initiative was funded by the National Center for Chronic Disease Prevention and Health Promotion. This is promoting nationwide adoption of associated devices such as masks, CPAP, IPAP, and APAP.
Key Sleep Apnea Devices Market Players:
- Philips Respironics
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- BMC Medical Co. Ltd.
- Curative Medical Inc.
- SOMNOmedics GmbH
- Itamar Medical Ltd.
- Nihon Kohden Corporation
- ResMed Inc.
- Natus Medical Incorporated
- Invacare Corporation
- Compumedics Limited.
- Signifier Medical Technologies Limited
The sleep apnea devices market is witnessing emergence from the developing countries, where key players are engaging in extensive R&D to develop new product lines. This is bringing diversity to this sector and creating a progressive atmosphere for other suppliers and manufacturers. Following the rise in remote healthcare, they are now focusing on the production of at-home monitoring and treatment modules. Furthermore, their marketing accomplishments are inspiring others to invest in this field. For instance, in June 2024, Signifier Medical Technologies achieved a milestone in the commercialization of eXciteOSA devices by securing a 10,000-unit order from Spectrum Sleep Solutions. Such key players are:
Recent Developments
- In January 2025, ResMed announced the commercial launch of its new OSA device, AirSense 11 AutoSet, in India. This next-generation CPAP tool is specifically designed to make it easier for individuals to start and stay on therapy by featuring auto-adjustment of air pressure.
- In March 2025, Signifier Medical Technologies launched a new addition, SKU 18010, to its eXciteOSA therapy. The new upgrade was intended to offer compliance with the reimbursement criteria of Medicare and Medicaid services, making it more accessible for patients.
Author Credits: Radhika Pawar
- Report ID: 183
- Published Date: Jun 13, 2025
- Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Sleep Apnea Devices Market Report Scope
Copyright @ 2025 Research Nester. All Rights Reserved.
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
See our insights in action - schedule your demo now!